Want to see CARL full AI Analyst Report?
CARL Stock Chart & Stats
$15.60
$0.65(6.02%)
At close: 4:00 PM EDT
$15.60
$0.65(6.02%)
Day’s Range― - ―
52-Week Range$8.50 - $17.23
Previous Close$11.45
Volume46.52K
Average Volume (3M)153.24K
Market Cap
$425.92M
Enterprise Value$214.83
Total Cash (Recent Filing)$89.22M
Total Debt (Recent Filing)$21.92M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Nov 05, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding27,302,744
10 Day Avg. Volume111,286
30 Day Avg. Volume153,242
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.78
Price to Sales (P/S)3.48
P/FCF Ratio-5.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.50Price Target Upside25.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.47
Revenue Forecast (FY)$76.71M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe acceleration in revenue growth indicates improving commercial traction and broader adoption of the company’s spine-surgery solutions. If sustained, stronger top-line expansion can improve operating leverage, support greater investment in digital planning capabilities, and strengthen market position over the coming quarters.
Strong Gross MarginsStable gross margins in the 72–75% range indicate attractive unit economics for the current product and service mix. This provides a solid foundation for future profitability because incremental revenue may contribute meaningfully toward operating expenses once the company scales its commercial platform.
Modest LeverageModest leverage gives Carlsmed more balance-sheet flexibility than a heavily indebted medical-device company. Lower debt burdens can reduce refinancing and interest pressure, preserving greater capacity to invest in growth initiatives while the business works toward improving operating profitability.
Bears Say
Deepening UnprofitabilityWidening losses despite faster revenue growth show that the current operating cost structure remains too heavy to support earnings. Persistent negative margins can delay self-funded expansion, weaken returns on capital, and require management to prioritize expense discipline before growth translates into durable shareholder value.
Persistent Cash BurnOperating cash burn has persisted and increased over the reported periods, demonstrating that the company is not yet funding its activities internally. Continued outflows may require external financing until profitability improves, creating dilution or funding pressure and limiting flexibility to pursue longer-term opportunities.
Unstable Equity FoundationThe sharp shift from negative equity to positive equity suggests that the balance sheet has been materially reshaped rather than strengthened through steady retained profits. This history signals financial fragility, while negative returns on equity indicate that the company has not yet converted its capital base into sustainable earnings.
Carlsmed, Inc. News
CARL FAQ
What was Carlsmed, Inc.’s price range in the past 12 months?
Carlsmed, Inc. lowest stock price was $8.50 and its highest was $17.23 in the past 12 months.
What is Carlsmed, Inc.’s market cap?
Carlsmed, Inc.’s market cap is $425.92M.
When is Carlsmed, Inc.’s upcoming earnings report date?
Carlsmed, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were Carlsmed, Inc.’s earnings last quarter?
Carlsmed, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.006.
Is Carlsmed, Inc. overvalued?
According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued.
Does Carlsmed, Inc. pay dividends?
Carlsmed, Inc. does not currently pay dividends.
What is Carlsmed, Inc.’s EPS estimate?
Carlsmed, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Carlsmed, Inc. have?
Carlsmed, Inc. has 27,302,744 shares outstanding.
What happened to Carlsmed, Inc.’s price movement after its last earnings report?
Carlsmed, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went up 1.032%.
Which hedge fund is a major shareholder of Carlsmed, Inc.?
Currently, no hedge funds are holding shares in CARL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carlsmed, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (25.00% Upside)
$19.50 (25.00% Upside)
Blogger Sentiment
Bullish
CARL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 23.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
121.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
CARL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: robust top-line growth (Q1 revenue +58%), significant surgeon adoption (+60% surgeon users YoY), production efficiencies (lead time cut >30%, gross margin +220 bps), compelling peer‑reviewed clinical outcomes (74% reduction in two-year revisions), and constructive reimbursement developments (NTAP renewal and proposed favorable CMS coding). Offsetting these positives are rising operating expenses (+61% YoY), deeper GAAP losses and negative adjusted EBITDA, and higher cash burn from operations. The company raised full-year revenue guidance and expects operating leverage as revenue scales, while some policy items remain preliminary. On balance, the business appears to be in a growth-investment phase with improving unit economics and strong market validation but elevated near-term losses as it invests to scale.View all CARL earnings summariesCARL Stock 12 Month Forecast
Average Price Target
$19.50
▲(25.00% Upside)
Technical Analysis
Ownership Overview
33.44% Insiders
6.12% Mutual Funds
6.53% Other Institutional Investors
51.42% Public Companies and
Individual Investors